Sivia Capital Partners LLC Grows Position in Novartis AG $NVS

Sivia Capital Partners LLC grew its stake in shares of Novartis AG (NYSE:NVS) by 83.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,595 shares of the company’s stock after buying an additional 6,175 shares during the period. Sivia Capital Partners LLC’s holdings in Novartis were worth $1,874,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Arlington Trust Co LLC purchased a new stake in shares of Novartis in the fourth quarter valued at $25,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Novartis in the third quarter valued at $33,000. South Plains Financial Inc. grew its position in shares of Novartis by 39.0% in the third quarter. South Plains Financial Inc. now owns 271 shares of the company’s stock valued at $35,000 after purchasing an additional 76 shares during the period. Aventura Private Wealth LLC purchased a new stake in shares of Novartis in the fourth quarter valued at $45,000. Finally, Cornerstone Planning Group LLC grew its position in shares of Novartis by 15,950.0% in the fourth quarter. Cornerstone Planning Group LLC now owns 321 shares of the company’s stock valued at $47,000 after purchasing an additional 319 shares during the period. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Sanford C. Bernstein raised Novartis to a “hold” rating in a research report on Thursday, March 19th. DZ Bank downgraded Novartis from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Argus upgraded Novartis from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Wednesday, March 11th. Citigroup reiterated a “buy” rating on shares of Novartis in a report on Thursday, February 5th. Finally, Wall Street Zen cut Novartis from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Price Performance

Shares of Novartis stock opened at $143.70 on Thursday. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46. The stock has a market capitalization of $274.20 billion, a P/E ratio of 20.59, a PEG ratio of 2.52 and a beta of 0.46. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96. The business’s fifty day moving average price is $149.60 and its 200 day moving average price is $147.14.

Novartis (NYSE:NVS) last issued its earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing analysts’ consensus estimates of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. During the same quarter in the previous year, the business posted $2.28 EPS. Novartis’s revenue was down .9% compared to the same quarter last year. As a group, research analysts anticipate that Novartis AG will post 8.84 earnings per share for the current year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.